|
0
Votes
vote
Med BioGene Reports Financial Results for the Third Quarter 2008VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 28, 2008) - Med BioGene Inc. (TSX VENTURE:MBI) today reported its financial results for the third quarter of 2008. Erinn Broshko, MBI's Chief Executive Officer stated: "This is an important time for the company as we prepare for the U.S. lau... |
|
3
Votes
vote
Gefitinib just as effective as chemotherapy for lung cancerGefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by resear... |
|
0
Votes
vote
Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancerAmgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small c... |
|
0
Votes
vote
Tissue analyses indicate survival benefits for some lung cancer patientsTaking small tissue samples from patients with lung cancer and examining them under a microscope (a procedure called histology) is now being utilized to better tailor the chemotherapy treatments to improve survival in some patients with non-small cell lung cancer, according to a study presented a... |
|
0
Votes
vote
Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancerThe combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic O... |
|
0
Votes
vote
Gender found to be play important role as a prognostic factor in people diagnosed with lung cancerEven though some combinations of gender, race and/or marital status can factor into the overall survival of nonoperative non-small cell lung cancer patients, gender is the most significant factor impacting overall survival, according to a study presented at the 2008 Chicago Multidisciplinary Symp... |
